Isaac joined ArchiMed in 2018, and has previously worked at Motive Partners (UK based Private Equity fund), HOF Capital (Global Venture Capital fund) and BioTechSpert (UK based Biotech advisory start-up).
Isaac holds a BA in Medical Studies from the University of Cambridge and an MSc in Finance and Private Equity from the London School of Economics (LSE), and has additionally completed courses in Nanotechnology and Business at the Universities of Shanghai Jiao Tong and Tokyo respectively. Isaac is currently undertaking a PhD at the University of Lancaster in Health Economics & Policy, focused on public and private investment strategies into ATMP’s.
In 2019, Isaac was selected as one of the “100 Biotech Leaders of the Future” by the Global Biotech Revolution.
Isaac is a British citizen and speaks French.